chronic kidney disease
Conditions
Interventions
intervention group:Naproxat mesylate + standard treatment group for COVID-19 infection
control group:standard treatment group for COVID-19 infection
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years old; 2. Hospitalized patients who meet the criteria for diagnosis and treatment of chronic kidney disease; 3. Those who tested positive for COVID-19 nucleic acid or antigen within 3 days before randomization.
Exclusion criteria
Exclusion criteria: 1. Serious hematological diseases, malignant tumors, and organ transplants; 2. Mental illness or other reasons can not cooperate with the treatment; 3. Allergic constitution, known allergic to the test drug (naphthalmositat mesylate) and its excipients; 4. Women who are pregnant, planning to become pregnant recently, or lactating; 5. Participants who have participated in other clinical trials within the last 1 month; 6. Researchers believe that there are other unsuitable candidates for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical improvement rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical recovery time;All-cause mortality at 14 and 28 days; | — |
Countries
China
Contacts
Public ContactZhang Ling
West China Hospital of Sichuan University
Outcome results
None listed